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Abstract: COPD is accompanied by limited physical activity, worse quality of life, and increased 
prevalence of depression. A possible link between COPD and depression may be irisin, a myo-
kine, expression of which in the skeletal muscle and brain positively correlates with physical 
activity. Irisin enhances the synthesis of brain-derived neurotrophic factor (BDNF), a neu-
rotrophin involved in reward-related processes. Thus, we hypothesized that mood disturbances 
accompanying COPD are reflected by the changes in the irisin–BDNF axis. Case history, routine 
laboratory parameters, serum irisin and BDNF levels, pulmonary function, and disease-specific 
quality of life, measured by St George’s Respiratory Questionnaire (SGRQ), were determined 
in a cohort of COPD patients (n=74). Simple and then multiple linear regression were used to 
evaluate the data. We found that mood disturbances are associated with lower serum irisin levels 
(SGRQ’s Impacts score and reciprocal of irisin showed a strong positive association; β: 419.97; 
95% confidence interval [CI]: 204.31, 635.63; P,0.001). This association was even stronger 
among patients in the lower 50% of BDNF levels (β: 434.11; 95% CI: 166.17, 702.05; P=0.002), 
while it became weaker for patients in the higher 50% of BDNF concentrations (β: 373.49; 95% 
CI: −74.91, 821.88; P=0.1). These results suggest that irisin exerts beneficial effect on mood 
in COPD patients, possibly by inducing the expression of BDNF in brain areas associated with 
reward-related processes involved in by depression. Future interventional studies targeting the 
irisin–BDNF axis (eg, endurance training) are needed to further support this notion.
Keywords: irisin, BDNF, SGRQ, whole-body plethysmography
Introduction
COPD, by profoundly impacting the patient’s quality of life, poses great socio-economic 
burden for individual patients, their families, and society.1,2 COPD primarily worsens 
quality of life by developing chronic, progressive dyspnea and consequent limitation 
of physical activity.3 Moreover, co-existing mental health problems show higher 
prevalence in COPD patients than in the general population,2,4 with depression and 
anxiety being present in ~20%–40% and 30%–50% of COPD cases, respectively.2,4–7 
Disturbance of mood not only causes disability per se but also changes the course of 
the disease by altering how patients experience and manage their disease, thus worsen-
ing their functional and health status.4,8 Therefore, the quest to elucidate the potential 
mechanisms underlying mood disturbances in COPD is ever so pressing.
Irisin is a recently identified putative contraction-regulated myokine that is formed 
by proteolytic cleavage of transmembrane fibronectin type III domain-containing 
protein 5 (FNDC5).9 Expression of FNDC5 was shown to positively correlate with 
physical activity in several organs (eg, skeletal muscle and brain) as its increased or 
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decreased expression was observed in response to sustained 
physical training or sedentary lifestyle, respectively.10–12 
It is interesting that FNDC5 expression has been shown 
in the ventral tegmental area (VTA) and hippocampus,13 
structures serving model-free and model-based reward-
related reinforcement learning processes.14,15 Irisin, the 
highly conserved fragment of FNDC5, is released into the 
systemic circulation to exert its most established effect of 
inducing white adipose tissue browning, activating oxygen 
consumption, and thermogenesis of fat cells.9,16 In addi-
tion, irisin may cross the blood–brain barrier to exert its 
influence in the central nervous system.17 Recently, based 
on preclinical models and clinical evidence, our group has 
proposed that irisin, by inducing brain-derived neurotrophic 
factor (BDNF) expression in VTA and hippocampus, may 
serve as a link between physical activity and reward-related 
learning and motivation.18 BDNF, a neurotrophin, has been 
associated with reward-related learning and consequent 
alteration of behavior.19 BDNF and its high-affinity recep-
tor tropomyosin-related kinase B are also expressed in the 
midbrain and hippocampus.12,20,21
Motivation and allied reward-related processes are often 
conceptualized using the reinforcement learning theorem, 
tied closely to the mesocortico-limbic system.14,15,22 Several 
disorders have been mapped onto the reinforcement learn-
ing paradigm including depression, with distinct attributes 
of value-based decision-making being altered. For example, 
higher discounting rates for delayed rewards reflective of 
hopelessness and unwillingness to invest in the future were 
shown in major depressive disorder.23 In a different study, 
anhedonia, one of the cardinal symptoms of major depressive 
disorder, was associated with diminished primary sensitivity 
to rewards.24 Accordingly, the dysfunction of VTA–ventral 
striatum axis has been specifically associated with anhedonia 
and anergy, also characteristic of depression.25
Summarizing, it may be proposed that change of reward 
processing in mood disorders may be accompanied by altera-
tion in the irisin–BDNF axis. Starting from this hypothesis, 
we set out to investigate the significant predictors of mood 
disturbance, with a special focus on the role serum irisin and 
BDNF play in a cohort of patients suffering from COPD, 
a disease associated with mental health problems including 
depressive symptoms.
Methods
study design and protocol
This study was designed in agreement with the STROBE 
statement for cross-sectional studies26 and is in line with 
the principles established by the Declaration of Helsinki. 
Approval of the Ethical Committee of the University of 
Debrecen (DEOEC RKEB/IKEB 3632-2012) was obtained 
in advance. Informed written consent was obtained from 
each participant.
In this study, data of our COPD cohort (described 
previously27) have been further analyzed. Briefly, every 
COPD patient, attending the outpatient unit of the Depart-
ment of Pulmonology (University of Debrecen) between 
September 1, 2012 and October 15, 2013, for the management 
of COPD, was screened by attending pulmonologists, who 
were unaware of the research hypothesis and study protocol. 
Patients suffering from any acute inflammatory disease over 
the preceding 1 month and those having benign or malignant 
tumors in their case history were excluded. Patients meet-
ing the entry criteria were referred to the study nurse who 
explained the details of the study and obtained informed 
consent. Every patient referred by the pulmonologists con-
sented to study participation. Overall, 74 COPD patients were 
recruited. At the time of inclusion, patients were managed 
for COPD according to the relevant Hungarian practice 
guideline28 and the GOLD initiative.29 Airway limitation was 
defined using the lower limit of normal.30–32 Patients received 
therapy at the time of inclusion as clinically warranted. 
Whole-body plethysmography was performed for every 
patient to obtain lung function parameters. Demographic, 
anthropometric, anamnestic, laboratory, and quality of life 
data were also acquired. Cumulative measure of smoking 
exposure was described by pack-years (accounted for both 
past and current smoking exposure). To assess disease-
specific quality of life, the official Hungarian version of Saint 
George’s Respiratory Questionnaire (SGRQ)33 was used with 
the permission of the proprietor (Paul Jones, University of 
London, London, UK).
Pulmonary function testing
Whole-body plethysmography was performed according to 
the ATS/ERS criteria34,35 with Piston whole-body plethys-
mograph (PDT-111/p; Piston Medical, Budapest, Hungary) 
equipped with automatic body temperature- and pressure-
saturated correction, furthermore, with full automatic cali-
bration and leakage test. Plethysmography was performed 
while patients were receiving long-term therapy for COPD. 
The best of three technically sound maneuvers was selected 
in case of each participant. Regarding resistance curves, at 
least two separate and technically appropriate measurements 
were performed (each measurement consists of recordings of 
at least five resistance loops) and results were accepted only if 
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these were the same for both measurements. Of the lung func-
tion parameters provided by the whole-body plethysmogra-
phy, the following data proved to be interesting in this study: 
airway resistance (R
aw
), forced expiratory volume in 1 second 
(FEV
1
), FEV
1
 as a percent of predicted value (FEV
1
% pred), 
forced vital capacity (FVC) as a percent of predicted value 
(FVC% pred), forced expiratory flow between 25% and 
75% of FVC (FEF25%–75%), FEF25%–75% as a percent 
of predicted value (FEF25%–75% % pred), residual volume 
(RV) as a percent of predicted value (RV% pred), ratio of RV 
to total lung capacity (TLC) as a percent of predicted value 
(RV/TLC% pred). For the statistical analysis, parameters 
showing Gaussian distribution were used in their raw forms, 
whereas those not normally distributed were appropriately 
transformed to obtain normal distribution.
Blood samples and routine laboratory 
tests
Blood samples were obtained in the morning of the examina-
tion, after an overnight fast. Routine laboratory investigations 
were performed by the Department of Laboratory Medicine 
(University of Debrecen) following their standard proce-
dures. Serum or plasma samples were used to characterize 
carbohydrate homeostasis (glucose, insulin, hemoglobin A1c 
[HgA1c]), lipid homeostasis (total cholesterol, triglyceride, 
low-density lipoprotein [LDL] cholesterol, high-density 
lipoprotein [HDL] cholesterol, lipoprotein (a), apolipopro-
tein A1 [ApoA1], apolipoprotein B [ApoB], kidney function 
(glomerular filtration rate [GFR], urea, creatinine), liver 
function (glutamate-oxaloacetate transaminase, glutamate-
pyruvate transaminase, gamma-glutamyltransferase), status 
of skeletal muscles (creatine kinase [CK], lactate dehydro-
genase), thyroid-stimulating hormone-sensitive (sTSH), and 
systemic inflammation (C-reactive protein, procalcitonin, and 
fibrinogen). From glucose and insulin concentrations, homeo-
static model assessment (HOMA) index was calculated as 
described previously.36 Serum samples used to determine 
irisin and BDNF were frozen within 60 minutes and stored 
at −80°C until further analysis.
Determination of serum irisin and BDnF
Serum BDNF levels were measured compliant with the 
manufacturer’s instructions (Sigma-Aldrich, St Louis, MO, 
USA). In short, standards and samples (diluted 100-fold) 
were administered into 96-well microplates coated with 
anti-BDNF monoclonal antibody and incubated overnight at 
4°C. Next, plates were washed four times, and then 100 µL 
biotinylated anti-human BDNF detector antibody was added 
to each well and incubated with gentle shaking for 1 hour. 
Afterwards, the wells were washed and 100 µL of horseradish 
peroxidase (HRP)-streptavidin solution was added to each 
well, followed by a 45-minute long incubation period at 
room temperature with gentle shaking. Samples were washed 
again, and then 100 µL TMB (3,3′,5,5′-tetramethylbenzidine) 
One-Step Substrate Reagent was added to each well and 
incubation was undertaken for 30 minutes to induce a color 
reaction. The reaction was stopped with manufacturer-
supplied stop solution. The absorbance at 450 nm was mea-
sured immediately with an automated microplate reader. All 
measurements were performed in duplicate. The detection 
limit for BDNF was ,80 pg/mL.
Serum irisin levels were assayed according to the 
manufacturer’s instructions using a commercially available 
enzyme-linked immunosorbent assay (ELISA) kit (Phoenix 
Pharmaceuticals, Burlingame, CA, USA). Briefly, 50 µL 
of standard or sample (diluted two times), 25 µL primary 
antibody, and 25 µL biotinylated peptide were added to each 
well, followed by a 2-hour long incubation period at room 
temperature. The plates were then washed four times and 100 
µL/well SA-HRP solution was added and incubated at room 
temperature for 1 hour. After washing, 100 µL/well of substrate 
solution was added followed by incubation for 1 hour, after 
which the reaction was terminated with 100 µL/well of 2 N 
HCl. Absorbance was read immediately at 450 nm. According 
to the manufacturer, the irisin standard curve was linear from 
1.34 to 29.0 ng/mL, and the detection limit was 1.34 ng/mL.
A standard curve showing linear relationship between 
optical density and concentration of irisin as well as BDNF 
was obtained with each plate. For the stratification of the 
final multiple regression model, serum BDNF levels were 
dichotomized according to their median value.
st george’s respiratory Questionnaire
The official Hungarian version of SGRQ validated for a 
1-month recall period was used according to the SGRQ 
manual supplied by the proprietor.37 SGRQ quantifies 
health impairment with three-component scores and one 
total score. The Symptoms score characterizes the patients’ 
perception of their recent respiratory problems in terms of 
their effect, frequency, and severity; Activity score quanti-
fies the impairment in daily physical activity; whereas the 
Impacts score characterizes a wide array of disturbances 
related to the psycho-social function. Importantly, Impacts 
score also strongly correlates with disturbances of mood (eg, 
depression). The Total score sums up the significance of the 
disease on overall health status. Scores are provided as a 
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percentage, thus 100% indicates the worst and 0% represents 
the best subjective health status. Differences in scores were 
considered clinically meaningful if they exceeded 4 percent 
points.38 Patients filled out the questionnaire by means of 
supervised self-administration. Two independent raters 
recorded data by diligently following data entry guidelines, 
and scoring was done using the score calculation algorithm 
provided by the developer of the SGRQ.39 Inter-rater variabil-
ity assessed by Spearman correlation was 0.99 (P,0.001), 
0.988 (P,0.001), 0.999 (P,0.001), and 0.999 (P,0.001) 
for the Symptoms, Activity, Impacts, and Total scores of 
SGRQ, respectively. Both raters were blinded to patients’ 
irisin and BDNF levels. For statistical analysis (and data 
presentation), the mean of scores was computed.
statistical analysis
Disturbances of mood were quantified with the Impacts 
score reflective of mood disorders and overall psycho-social 
dysfunction.
The mean of the Impacts score was used as cutoff for 
dichotomization of the COPD cohort, so patients with Impacts 
score ,32.65% were put into the lower Impacts score group 
(n=40), while patients with Impacts score $32.65% formed 
the higher Impacts score group (n=34), corresponding to less 
or more pronounced mood disturbances, respectively.
Normality of continuous variables was checked by the 
Shapiro–Wilk test. For variables following Gaussian distri-
bution, two data sets were compared using Student’s t-test, 
whereas Mann–Whitney U-test was carried out for those not 
showing normal distribution. Frequencies were compared 
with Pearson’s χ2 test.
The correlation of mood disturbance and serum irisin 
concentration was established using Spearman’s correla-
tion. The relationship between mood disturbance and serum 
irisin level was further investigated with simple as well as 
multiple linear regression. To ensure normal distribution of 
variables for these analyses, CK, total cholesterol, triglyc-
eride, LDL cholesterol, HDL cholesterol, ApoA1, ApoB, 
insulin, HgA1c, sTSH, HOMA index, FEF25%–75%, RV, 
and RV% pred were log-transformed; furthermore, square 
root of disease duration, reciprocal of irisin, and reciprocal 
of square of glucose concentration were computed.
Simple linear regression was carried out with traditional 
confounding factors (age, gender, height, and disease duration 
in years), lung function parameters, and routine laboratory 
parameters obtained from the serum or plasma samples. Miss-
ing data were omitted. To eliminate the effects of potential con-
founders, multiple linear regression modeling was performed. 
First, the least parsimonious multiple model was compiled 
including all significant regressors identified by means of 
simple linear regression and a priori variables (age and gen-
der). Variables were introduced into the initial multiple model 
simultaneously, and then factors not contributing significantly 
to the model were deleted (except for the a priori variables). The 
final model contained (in addition to the a priori parameters) 
FEV
1
% pred, body mass index, weight, and (log) triglyceride 
levels. Furthermore, the final model was stratified with respect 
to BDNF levels. Heteroskedasticity and goodness of fit for the 
model were assessed by Cook–Weisberg and Ramsey test.
Statistical analysis was performed with Stata 13.0 software 
StataCorp. 2013. Stata Statistical Software: Release 13. Col-
lege Station, TX: StataCorp LP). Values are given as mean ± SD 
or median (with the interquartile range: IQR), and regres-
sion coefficients are presented with their 95% confidence 
interval (95% CI).
Results
Patients
The baseline characteristics of our COPD patient cohort 
were detailed previously.27 Demographic, anthropometric 
characteristics, medication history, pulmonary function, and 
disease-specific health impairment measures are summarized 
in Table 1.
Comparison of patients with respect 
to mood disturbance
The two groups of COPD patients, dichotomized with respect 
to the mean of Impacts score, proved to be homogeneous 
regarding most of the parameters investigated. Neverthe-
less, in the group with higher Impacts score (showing more 
pronounced impairment of mood), dyslipidemia, and hyper-
tension (as anamnestic data) were more frequent; serum LDL 
cholesterol, serum irisin, FEV
1
% pred, and FVC% pred were 
significantly lower; whereas serum glucose was significantly 
higher than the corresponding values in the group with lower 
Impacts score (showing less despair) (Table 2).
associations among sgrQ’s Impacts 
score, serum irisin, and BDnF levels
Upon assessing the correlation between the Impacts score 
and reciprocal of irisin, we found a significant positive cor-
relation in the whole COPD cohort (Spearman correlation 
coefficient: 0.26, P=0.02; Figure 1), in agreement with the 
finding that irisin concentration was smaller in the higher 
Impacts score group (Table 2). This correlation became 
stronger (and remained almost statistically significant) in the 
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linear regression, the regression coefficient failed to reach 
statistical significance (P=0.08; Table 3). However, after 
adjusting for all significant predictors and a priori determi-
nants by means of multiple linear regression, the Impacts 
score and reciprocal of irisin showed a strong, significant, 
positive association (β: 419.97; 95% CI: 204.31, 635.63; 
P,0.001) (Table 4). This association became even more 
distinct among patients with lower BDNF levels (β: 434.11; 
95% CI: 166.17, 702.05; P=0.002), while a considerably 
weaker and statistically nonsignificant association was pres-
ent in case of patients with higher BDNF concentrations (β: 
373.49; 95% CI: −74.91, 821.88; P=0.10). All three models 
were significant (P,0.001, 0.001, and 0.009) (Table 5). The 
Cook–Weisberg test showed no heteroskedasticity for the 
full model and strata with lower and higher BDNF (P=0.92, 
0.67, and 0.82, respectively). Furthermore, all three models 
showed good fit reflected by the locally weighted scatterplot 
smoothing (Figure 2) as well as by the Ramsey test (P=0.82; 
0.53, and 0.79 for the whole data set and strata with lower 
and higher BDNF, respectively).
Based on the final multiple linear regression model (built 
for the Impacts score), body mass index, log triglyceride, 
and body weight were significantly associated with mood 
disturbances among COPD patients. In addition, severity of 
airflow limitation, characterized by FEV
1
% pred, showed 
a significant negative association with the Impacts score 
(β: −0.52; 95% CI: −0.71, −0.32; P,0.001) (Table 4).
Discussion
The main finding of this study is that the reciprocal of 
serum irisin level shows significant positive correlation 
with the Impacts score of SGRQ in COPD patients. Thus, 
more pronounced disturbance of mood (indicated by higher 
Impacts score) is accompanied by lower irisin levels. This 
effect has proven even more prominent among patients with 
lower BDNF levels, but became nonsignificant in patients 
possessing higher BDNF concentrations. Analysis by means 
of multiple linear regression that corrects for possible con-
founders has confirmed the significant association between 
Impacts score and serum irisin; furthermore, it also revealed 
four other significant determinants of Impacts score: BMI, 
weight, triglyceride level, and FEV
1
% pred, an index of the 
severity of airflow limitation in COPD.29
Several studies have corroborating evidence for the 
relationship between markers of disease severity and BMI. 
Recently, the COPD Gene investigators analyzed the data of 
3,631 spirometry-confirmed COPD patients obtained from a 
multicenter prospective cohort study. The investigators found 
Table 1 Main characteristics of the whole COPD cohort (n=74)
Parameters Data
age (years) 62.15±9.70
gender (female/male) 27/47
smoker 25/74 (33.8%)
smoking (pack-years) 20.00 (5.25–33.75)
smoking (years) 10.00 (0.00–33.00)
Diabetes present 13/74 (17.6%)
Dyslipidemia present 26/74 (35.1%)
hypertension present 43/74 (58.1%)
Disease duration (years) 5.00 (3.00–10.00)
Waist (cm) 101.99±14.31
Weight (kg) 79.71±17.12
height (m) 1.68±0.094
BMI (kg/m2) 28.19±5.09
Irisin (ng/ml) 7.22 (6.63–8.10)
BDnF (ng/ml) 345.6 (294.20–387.90)
CK (U/l) 101.00 (74.00–139.00)
lDh (U/l) 208.62±34.98
glucose (mmol/l) 5.00 (4.20–5.80)
Insulin (mU/l) 8.95 (5.55–16.50)
hga1C (%) 5.70 (5.50–6.10)
hOMa index 2.14 (1.14–4.67)
Cholesterol (mmol/l) 5.30 (4.00–6.30)
lDl-C (mmol/l) 3.10 (2.60–3.70)
hDl-C (mmol/l) 1.40 (1.20–1.80)
Triglyceride (mmol/l) 1.35 (1.00–2.00)
CrP (mg/l) 2.00 (1.21–4.00)
Fibrinogen (g/l) 3.67 (3.25–4.00)
Procalcitonin (µg/l) 0.00 (0.00–0.00)
sgrQ symptoms score 32.66 (13.64–58.28)
sgrQ Impacts score 29.64 (15.44–49.79)
sgrQ activity score 57.32 (47.24–72.08)
sgrQ Total score 41.08±20.99
FeV1 (l/s) 1.86±0.72
FeV1% pred 66.54±20.29
FeF25%–75% (l/s) 1.18 (0.65–1.81)
FeF25%–75% % pred 35.50 (24.00–55.00)
rV/TlC 54.45±10.08
rV/TlC% pred 139.97±21.27
FVC (l) 2.75 (2.23–3.39)
FVC% pred 82.54±17.44
raw (kPa⋅s/l) 0.27 (0.22–0.42)
Note: Data are presented as mean ± sD or median (interquartile range) unless 
otherwise stated.
Abbreviations: BDnF, brain-derived neurotrophic factor; BMI, body mass index; 
CK, creatine kinase; CrP, C-reactive protein; FeV1, forced expiratory volume 
in 1 second; FVC, forced vital capacity; hDl, high-density lipoprotein; hOMa, 
homeostatic model assessment; lDh, lactate dehydrogenase; lDl, low-density 
lipoprotein; rV, residual volume; sD, standard deviation; sgrQ, st george’s 
respiratory Questionnaire; TlC, total lung capacity.
stratum with lower BDNF level, while it was weaker (and 
non-significant) in the stratum with higher BDNF (Spearman 
correlation coefficient: 0.32 and 0.22, P=0.055 and 0.19, 
respectively).
When the relationship between the Impacts score and 
reciprocal of serum irisin level was analyzed with simple 
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Table 2 Main characteristics of two groups of the COPD cohort dichotomized according to mood disturbances indicated by the 
Impacts score
Parameters Lower Impacts score Higher Impacts score P-value
age (years) 62.75±9.15 61.44±10.40 0.567
gender (female/male) 12/28 15/19 0.209
smoker 13/40 (32.5%) 12/34 (35.3%) 0.800
smoking (pack-years) 19 (2.25–33) 20 (8.8–37.5) 0.227
smoking (years) 5.50 (0.00–30.00) 12.50 (0.00–38.00) 0.460
Diabetes present 5/40 (12.5%) 8/34 (23.5%) 0.214
Dyslipidemia present 9/40 (22.5%) 17/34 (50.0%) 0.017
hypertension present 18/40 (45.0%) 25/34 (73.5%) 0.013
rr systolic (mmhg) 135.45±15.34 137.70±16.60 0.545
rr diastolic (mmhg) 83.00±14.62 81.65±13.60 0.683
Prior aMI 4/40 (10.0%) 5/34 (14.7%) 0.538
Prior stroke (n/y) 0/40 (0%) 1/34 (2.9%) 0.275
Disease duration (years) 5.00 (3.00–8.00) 6.00 (3.00–10.00) 0.301
Waist (cm) 101.11±13.04 103.02±15.81 0.570
Weight (kg) 78.77±15.41 80.81±19.13 0.617
height (m) 1.70±0.94 1.65±0.10 0.110
BMI (kg/m2) 27.29±4.25 29.25±5.82 0.103
Irisin (ng/ml) 7.37 (6.99–8.12) 6.85 (6.49–7.99) 0.030
BDnF (ng/ml) 347.55 (316.10–413.60) 343.15 (292.00–377.90) 0.400
Urea (mmol/l) 5.31±1.30 5.31±1.47 0.995
Creatinine (µmol/l) 69.50 (57.50–81.50) 72.00 (61.00–80.00) 0.840
gFr (ml/min/1.73 m2) 90.00 (81.50–91.00) 91.00 (80.00–91.00) 0.920
gOT (U/l) 20.00 (16.00–24.00) 19.00 (15.00–22.00) 0.384
gPT (U/l) 20.50 (14.50–29.50) 1.00 (13.00–21.00) 0.102
γgT (U/l) 32.50 (19.50–49.00) 32.50 (20.00–47.00) 0.724
CK (U/l) 101.50 (77.50–138.50) 93.50 (73.00–147.00) 0.640
lDh (U/l) 207.55±36.08 209.88±34.12 0.780
glucose (mmol/l) 4.08 (4.00–5.50) 5.30 (4.70–6.60) 0.015
Insulin (mU/l) 7.50 (5.30–13.50) 9.45 (5.90–22.40) 0.243
hga1c (%) 5.70 (5.45–6.00) 5.70 (5.50–6.20) 0.550
hOMa index 1.48 (1.00–3.38) 2.35 (1.46–5.92) 0.092
Cholesterol (mmol/l) 5.70 (4.00–6.30) 5.00 (4.00–5.80) 0.112
lDl-C (mmol/l) 3.25 (2.65–4.00) 2.80 (2.40–3.30) 0.030
hDl-C (mmol/l) 1.45 (1.20–1.80) 1.35 (1.00–1.80) 0.570
Triglyceride (mmol/l) 1.35 (0.95–1.95) 1.35 (1.00–2.00) 0.691
CrP (mg/l) 1.90 (0.85–3.65) 2.60 (1.50–7.00) 0.060
Fibrinogen (g/l) 3.63 (3.13–4.00) 3.69 (3.33–4.00) 0.543
Procalcitonin (µg/l) 0.00 (0.00–0.00) 0.00 (0.00–0.00) 0.360
sTsh (mU/l) 1.36 (0.84–2.00) 1.12 (0.78–1.43) 0.216
FeV1% pred 71.37±19.26 60.85±20.25 0.025
FVC% pred 86.3±16.92 78.12±17.25 0.043
Notes: Patients in the lower and higher Impacts score groups had smaller and higher (or equal) Impacts score than (or to) 32.65%, respectively, with 32.65% being the mean 
Impacts score of the whole cohort. Data are presented as mean ± sD or median (interquartile range), unless otherwise stated. Differences between the two groups were 
considered significant at P,0.05 (indicated in bold).
Abbreviations: aMI, acute myocardial infarction; BDnF, brain-derived neurotrophic factor; BMI, body mass index; CK, creatine kinase; CrP, C-reactive protein; FeV1, forced 
expiratory volume in 1 second; FVC, forced vital capacity; GFR, glomerular filtration rate; GOT, glutamate-oxaloacetate transaminase; GPT, glutamate-pyruvate transaminase; 
hDl, high-density lipoprotein; hOMa, homeostatic model assessment; lDh, lactate dehydrogenase; lDl, low-density lipoprotein; rr, blood pressure measured according 
to riva-rocci; sTsh, thyroid-stimulating hormone-sensitive; γgT, gamma-glutamyltransferase.
significant association between obesity, characterized by 
higher BMI and worse outcomes including poorer quality of 
life, dyspnea, and reduced 6-minute walk distance. Further-
more, greater odds for acute exacerbations were observed, 
independent of the presence of comorbidities.40 Furthermore, 
Ho et al41 have also reported significant correlation between 
FEV
1
% (FEV
1
/FVC) and BMI (Spearman’s correlation 
coefficient 0.255, P,0.01). In another study, the influence 
of metabolic syndrome and its components on the 5-year 
mortality was assessed in COPD. The authors found that 
100 mg/dL increase of plasma triglyceride concentration 
increases the probability of death over the 5 years by 39% 
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Similarly, in another study, significant negative correlation 
between FEV
1
% pred and the Total score was described in 
a sample of severe COPD patients (r=−0.4, P,0.001).46 
In a double-blind placebo-controlled study designed to assess 
the benefits of the fixed combination inhaler fluticasone 
propionate and salmeterol versus placebo, the longitudinal 
analysis of data for 4,951 COPD patients showed significant 
negative correlation regarding the change in SGRQ scores 
and FEV
1
 during the 3 years of the study in all treatment 
arms, combined.47 Previously, we also found a significant 
negative correlation between the Total SGRQ score and 
FEV
1
% pred.27
???
??
??
??
??
????? ??? ???? ????????????????????????????????????????? ????
????????????????????????????????????????????
???
????
????
????
??
Figure 1 Correlation of mood disturbance (characterized by the Impacts score of 
sgrQ) and reciprocal of serum irisin concentration in the whole data set (n=74).
Notes: The x-axis shows the reciprocal of serum irisin level (in ng/ml), whereas 
the y-axis denotes the Impacts score of SGRQ. The blue line shows the fitted line 
to the data points (represented by the green dots), whereas the grey zone indicates 
the 95% CI.
Abbreviations: CI, confidence interval; SGRQ, St George’s Respiratory Ques-
tionnaire.
Table 3 Significant predictors of reciprocal of serum irisin 
level and Impacts score of sgrQ determined with simple linear 
regression for the whole COPD cohort (n=74)
Parameter Coefficient (95% CI) P-value
Simple linear regression of reciprocal of irisin
Waist circumference 0.00045 (0.00015, 0.00075) 0.004
Weight 0.00027 (0.00002, 0.00052) 0.036
reciprocal of glucose  
square
−0.31 (−0.56, −0.06) 0.014
log hga1c 0.043 (0.008, 0.077) 0.016
Urea 0.0035 (0.00027, 0.0068) 0.034
lDh −0.00014 (−0.00026, −9.94∙10−6) 0.035
log triglyceride 0.011 (0.0033, 0.019) 0.006
log hDl cholesterol −0.022 (−0.035, −0.008) 0.002
FVC 0.0061 (0.00084, 0.011) 0.024
FeV1 0.0068 (0.0006, 0.013) 0.032
rV/TlC% pred −0.0023 (−0.00043, −0.00002) 0.03
Simple linear regression of Impacts score
height −57.86 (−109.01, −6.65) 0.027
sqrt of disease duration 5.52 (0.89, 9.58) 0.019
reciprocal of glucose  
square
−369.63 (−635.69, −103.58) 0.007
log hga1c 44.97 (7.58, 82.37) 0.019
CrP 0.95 (0.19, 1.72) 0.015
log cholesterol −21.41 (−39.21, −3.61) 0.019
log lDl cholesterol −15.56 (−28.7, −2.42) 0.021
log hOMa index 5.82 (1.29, 10.56) 0.012
BMI 1.16 (0.23, 2.1) 0.016
log sTsh −9.89 (−17.35, −2.43) 0.01
FVC −10.04 (−15.36, −4.73) ,0.001
FVC% pred −0.39 (−0.66, −0.12) 0.005
FeV1 −12.24 (−18.5, −5.99) ,0.001
FeV1% pred −0.38 (−0.61, −0.15) 0.001
FeF25%–75% −7.01 (−12.96, −1.06) 0.022
log FeF25%–75% % pred −9.45 (−17.91, −1) 0.029
rV/TlC 0.62 (0.15, 1.08) 0.01
rV/TlC% pred 0.34 (0.12, 0.55) 0.03
Note: Regression coefficient values are presented with their 95% CI.
Abbreviations: BMI, body mass index; CI, confidence interval; CRP, C-reactive 
protein; FeV1, forced expiratory volume in 1 second; FVC, forced vital capacity; 
hDl, high-density lipoprotein; hOMa, homeostatic model assessment; lDh, 
lactate dehydrogenase; lDl, low-density lipoprotein; rV, residual volume; sgrQ, 
st george’s respiratory Questionnaire; sQrT, square root; TlC, total lung capacity; 
sTsh, thyroid-stimulating hormone-sensitive.
(translating into a hazard ratio of 1.39, 95% CI: 1.06, 1.83).42 
This finding corroborates our result that log triglyceride levels 
were significantly associated with the Impacts score in our 
final multiple linear regression model (Table 4). Moreover, 
the possibility for a common pathomechanism of COPD 
and depressive disorders was also suggested based on the 
results of an interventional study. Patients were enrolled 
in a complex exercise program (2 hours per day, 5 days 
per week, for 6 weeks) supervised by physiotherapists and 
lung specialists. At follow-up, improvement of depressive 
symptoms paralleled by significant reduction of BMI was 
reported in the subgroup of patients showing signs of depres-
sion at baseline.43 These findings could be explained by our 
proposition that exercise-induced increase in irisin levels 
may simultaneously induce white adipocyte browning and 
consequent weight loss and enhance mood via activation of 
the BDNF pathway in specific brain areas (eg, hippocampus, 
VTA) involved in affective disorders.
Prognostic value of FEV
1
% pred regarding population-
level clinical outcomes is acknowledged by the Global 
Strategy for the Diagnosis, Management, and Prevention 
of Chronic Obstructive Pulmonary Disease (2017 report).44 
FEV
1
% pred is also predictive of health status and the rate 
of exacerbations in COPD and it is closely interconnected 
with alteration of mood and psychosocial function.30 The 
significant inverse relationship between Impacts score and 
FEV
1
% pred is also in line with previous findings. Significant 
negative correlation between FEV
1
% pred and all components 
(Symptoms, Impacts, Activity) and the total score of SGRQ 
was previously described in a cohort of Hispanic smokers.45 
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Table 4 Multiple linear regression model for the sgrQ’s Impacts 
score of the whole COPD cohort and its strata with respect to 
the median BDnF level
Parameter Coefficient (95% CI) P-value
Whole cohort
reciprocal of irisin 419.97 (204.31, 635.63) 0.000
age −0.42 (−0.85, 0.01) 0.053
gender 0.45 (−9.92, 10.83) 0.931
FeV1% pred −0.52 (−0.71, −0.32) 0.000
BMI 3.68 (2.01, 5.34) 0.000
log triglyceride −8.70 (−16.38, −1.02) 0.027
Weight −0.78 (−1.31, −0.25) 0.004
Lower BDNF stratum
reciprocal of irisin 434.11 (166.17, 702.05) 0.002
age −0.39 (−0.94, 0.16) 0.160
gender −3.87 (−23.46, 15.72) 0.689
FeV1% pred −0.50 (−0.76, −0.23) 0.001
BMI 3.45 (0.49, 6.42) 0.024
log triglyceride −11.91 (−22.31, −1.50) 0.026
Weight −0.58 (−1.60, 0.43) 0.250
Higher BDNF stratum
reciprocal of irisin 373.49 (−74.91, 821.88) 0.099
age −0.49 (−1.38, 0.40) 0.269
gender 1.19 (−15.55, 17.94) 0.885
FeV1% pred −0.56 (−0.93, −0.19) 0.004
BMI 3.70 (1.25, 6.15) 0.005
log triglyceride −4.62 (−18.32, 9.07) 0.494
Weight −0.83 (−1.59, −0.07) 0.033
Notes: Regression coefficient values are presented with their 95% CI. The 
initial model for the multiple linear regression analysis consisted of the significant 
parameters provided by the simple linear regression and the relevant a priori 
identified parameters (age, gender). P-values ,0.05 are indicated in bold.
Abbreviations: BDnF, brain-derived neurotrophic factor; BMI, body mass index; 
CI, confidence intervals; FEV1, forced expiratory volume in 1 second; sgrQ, 
st george’s respiratory Questionnaire.
Table 5 ANOVA tables describing the final model for the whole 
cohort (Panel a), lower BDnF stratum (Panel B), and higher BDnF 
stratum (Panel C)
Panel SS df MS
A
Model
residual
Total
15,192.92
15,875.15
31,068.07
7
64
71
2,170.42
248.05
437.58
n=72
F (7, 64) =8.75
P,0.001
R2=0.489
adj R2=0.433
root Mse =15.75
B
Model
residual
Total
7,877.75
6,880.71
14,758.46
7
29
36
1,125.39
237.27
409.96
n=37
F (7, 29) =4.74
P=0.0012
R2=0.534
adj R2=0.421
root Mse =15.40
C
Model
residual
Total
7,576.25
8,545.32
16,121.57
7
27
34
1,082.32
316.49
474.16
n=35
F (7, 29) =3.42
P=0.0095
R2=0.4699
adj R2=0.3325
root Mse =17.79
Note: Data regarding the weight of two patients were missing; thus, they were not 
included in the analysis.
Abbreviations: anOVa, analysis of variance; BDnF, brain-derived neurotrophic 
factor; df, degree of freedom; Ms, mean of the sum of squares; Mse, mean squares 
of error; ss, sum of squares.
Our present analysis showed a very strong positive asso-
ciation between the Impacts score, reflective of depressive 
mood disturbances in COPD and the reciprocal of serum 
irisin (Table 4) that was substantially more remarkable in the 
stratum with BDNF levels lower than the sample median. 
In addition to reciprocal of irisin, regression coefficients 
remained significant for FEV
1
% pred, BMI, and log triglyc-
eride in the stratum with lower BDNF levels. However, only 
FEV
1
% pred, BMI, and weight showed significant contribu-
tion to the final model in the stratum with higher BDNF levels 
(Table 4). These results suggest the presence of an interaction 
between serum irisin and serum BDNF levels regarding their 
influence on Impacts score and they underscore our previous 
hypothesis that serum irisin may exert a peripheral effect 
reflected by the alteration of metabolic parameters (BMI, 
weight, and serum triglyceride levels) and a central effect 
related to mood and motivation based on BDNF’s action.
The role of BDNF in depressive disorders has been 
articulated by the neurotrophic hypothesis of depression. 
???
??
??
??
??
????? ??? ???? ????????????????????????????????????????? ????
??????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????????????????????? ?????????????
???
????
????
????
??
Figure 2 The model describing the correlation between the Impacts score of sgrQ 
and reciprocal of serum irisin concentration in the whole data set (n=74).
Notes: The x-axis shows the reciprocal of serum irisin concentration (in ng/ml), 
whereas the y-axis denotes the Impacts score of sgrQ. The blue and red dots 
indicate the raw and fitted values obtained by multiple linear regression, respectively. 
The green and orange lines indicate the curves fitted to the raw data and to 
data provided by multiple linear regression. Fitting was done by locally weighted 
scatterplot smoothing (lowess).
Abbreviation: sgrQ, st george’s respiratory Questionnaire.
According to this, depression is based on neurotrophin defi-
ciency of the limbic system, an effect that may be reversed by 
long-term administration of antidepressants.48,49 This hypoth-
esis is closely linked to the neural plasticity hypothesis, 
which postulates that environmental factors (eg, stress) 
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cause dysfunction of signal transduction cascades involved 
in neuronal adaptation and plasticity. A candidate pathway 
is that containing BDNF-cAMP response element-binding 
protein, a transcription factor.49
Changes in BDNF plasma levels as well as tissue lev-
els from postmortem biopsies of hippocampus have been 
described in depressed patients.49 Furthermore, the cause–
effect relationship between BDNF and major depressive 
disorder was established by a case–control study nested in 
a cohort of 1,276 women aged 75–84 years. Using incident 
cases and controls over the 4-year observation period, the 
authors concluded that BDNF is a state marker of major 
depressive disease based on the longitudinal decrease of 
serum BDNF levels in this cohort.50 Corroborating evi-
dence from a systematic review and meta-analysis of 20 
publications including 1,504 participants, furthermore, 
showed significant correlation between changes of BDNF 
level and depression score as well as significant increases 
of BDNF levels accompanied therapy with antidepres-
sants.51 Nevertheless, it should be noted that, despite the 
accumulating preclinical and clinical evidence, there are 
some controversies related to the role BDNF plays in the 
evolution of depression, as inconsistent observations ques-
tioning this hypothesis were also reported.52,53 However, 
these discrepancies may stem from the methodological dif-
ferences like variance of patient populations, sample size, 
treatment schedules, disease severity, and assessment tools 
quantifying disease severity.52
To the best of our knowledge, this is the first time that the 
irisin–BDNF axis was assessed with respect to its possible 
influence on mood disturbances in COPD patients. The ability 
of exercise to induce BDNF expression in the hippocampus 
via induction of the FNDC5–irisin pathway has been reported 
previously in mice.12 Our present results seem to support 
these findings in humans for the first time.
Limited number of reports deals with the alteration of 
serum irisin and BDNF levels in COPD patients. Irisin 
levels were shown to be lower in COPD patients than in 
controls (31.6 [IQR: 22.7–40.4] ng/mL and 50.7 [IQR: 
39.3–65.8] ng/mL, respectively; P,0.001).54 This tendency 
was present even when patients were divided into subgroups 
with respect to the level of physical activity: in patients with 
lower physical activity, serum irisin levels were 23.1 (IQR: 
17.3–27.0) ng/mL and 39.6 (IQR: 36.0–43.7) ng/mL in 
COPD and control patients, respectively.54 Others reported 
comparable irisin levels of 26.3 (IQR: 22.6–32.4) ng/mL, 
53.7 (IQR: 46.7–62.8) ng/mL, and 58.5 (42.8–78.9) ng/mL 
in smokers with and without COPD and in non-smoking 
individuals, respectively.55 While the serum BDNF levels 
measured in our study are higher than those in the study of 
Stoll et al that included COPD patients,56 they are within 
the magnitude measured in other studies involving healthy 
individuals and other patient populations. The reported serum 
BDNF levels span over five orders of magnitude, ranging 
from 0.005 to 280 ng/mL,50,52,57,58 depending on the use of 
different ELISA kits.
A possible limitation of this study comes from its design 
(cross-sectional study), limiting the possibility to draw cause 
and effect conclusions. Due diligence was exercised to 
counterbalance the effect of possible confounders by using 
multiple linear regression to account for their effect. Char-
acterizing disturbance of mood by the Impacts component 
score of the SGRQ may also be viewed as a possible short-
coming. Identification of depression based on the Diagnostic 
and Statistical Manual of Mental Disorders 5 may prove to 
be challenging as accompanying somatic symptoms could 
be secondary to either depression or COPD.43 Furthermore, 
utility of certain diagnostic instruments, for example, hospital 
anxiety and depression scale, has been questioned with 
respect to their accuracy in COPD patients.59 Nevertheless, 
strong correlation between the Impacts score and depression 
has been described previously,8,60 allowing us to propose that 
irisin is a possible link between both metabolic disturbances 
and affective changes. The absence of postbronchodilator 
whole-body plethysmography may also be viewed as a limita-
tion; however, as previously described,27 this patient popu-
lation has been included in a COPD management program 
for a median of 5 (IQR: 3–10) years, hence patients already 
received bronchodilator therapy and were asked to take their 
medications as usual in the morning of the examinations. 
Thus, the current results should be interpreted as on-treatment 
results. Summarizing, future prospective studies are needed 
to further underscore the propositions laid out in our current 
work. Nevertheless, this investigation has several merits like 
the relatively large clinical patient sample, the use of special 
tools (whole-body plethysmography and SGRQ, a validated 
disease-specific questionnaire), furthermore, the stringent 
data analysis resulting in powerful findings.
In summary, we have found a significant inverse relation-
ship between severity of mood disturbance and serum irisin 
levels among COPD patients. The fact that this correlation 
was considerably more influential among patients with BDNF 
levels below the sample median further supports the possibil-
ity that, in COPD, irisin links deterioration of mood to the 
central effects of BDNF exerted in areas closely associated 
with reward-related processes involved in the evolution 
of depression. Furthermore, our findings have a possible 
practical implication as the efficacy of disease management 
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programs has been shown to depend greatly on the patients’ 
ability to utilize personal resources like motivation to alter 
behavior and willingness to set new goals.61 Nonadherence 
to standard care is very frequent among COPD patients 
reaching ~70%.3 Considering these aspects, a further con-
sequence of altered irisin–BDNF axis (and downstream 
processes including mesocortico-limbic dysfunction) may 
be the impairment of reward-related motivation, prevent-
ing change of behavior needed for COPD management and 
causing lack of efficacy of disease management programs. 
Future interventional studies investigating the potential 
beneficial effect of endurance training tailored to the needs 
of COPD patients with respect to change of irisin–BDNF 
levels as well as mood and motivation are needed to further 
support this notion.
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